A Phase 2 interventional study of Cohort 1 - Group 1 JNJ High Dose and Cohort 1 - Group 2 JNJ Medium Dose in Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Dengue by National Institute of Allergy and Infectious Diseases (NIAID) — 1 open to participants now, 1 under way, none of them phase 3. Dengue · National Institute of Allergy and Infectious Diseases (NIAID).
Among the 35 studies in Dengue by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 15th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 2, and was the 34th registered.
283 studies on the registry are indexed under Dengue; 44 are open to participants now.
Browse Dengue studies →1 of the 35 studies in Dengue by National Institute of Allergy and Infectious Diseases (NIAID) is open now, in 1 country. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2022.
This study's enrollment of 56 is below the median of 132 across 197 interventional studies indexed under Dengue.
Median enrollment 56 across the 32 interventional studies, 775 across the 3 observational. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Dengue by National Institute of Allergy and Infectious Diseases (NIAID), from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a placebo with respect to its antiviral activity in healthy adult participants inoculated with Dengue Serotype 3.
This study is a multicenter, randomized, placebo-controlled, double-blind, interventional Phase 2a, study in normal healthy adult subjects 18 - 55 years of age, inclusive, recruited from the metropolitan Baltimore/Washington, DC area \& Burlington/Vermont. The study follows an adaptive 2-stage design consisting of 2 cohorts, each with up to 3 groups. The 2 cohorts will be enrolled in a staggered manner. As a safety measure, a sentinel group of 4 participants will be enrolled in Cohort 1 (Group 1a) before enrolling the remaining participants (Group 1b and Group 2) in the cohort.
The purpose of this study is to evaluate the clinical and virologic response to repeated doses of investigation product JNJ-64281802 when administered orally in healthy, DENV and ZIKV-naïve, non-pregnant, adult volunteers who are subsequently inoculated with rDEN3delta30, a recombinant DENV-3 strain, to explore the antiviral activity of repeated oral doses of JNJ-64281802 versus placebo. The safety, tolerability, PK, and the relationship between the PK and antiviral activity of JNJ-64281802 will also be evaluated. Placebo recipients are included in the study as a control to better assess study agent associated versus non-study agent associated AEs and to act as infectivity controls following administration of rDEN3delta30.
After providing written informed consent, subjects will undergo eligibility screening, including medical history, physical examination, hematology testing, liver and renal function testing, human immunodeficiency virus (HIV) screening, hepatitis B and C screening, urinalysis, urine toxicology screening, ECG screening, alcohol breath test screening (per PI/provider discretion), COVID-19 testing (if determined necessary by the clinician or per guidelines), and serology screening for previous infection of DENV and ZIKV (Cohort 1) and DENV, ZIKV, West Nile virus, and SLEV (Cohort 2).
Serum or urine pregnancy testing will be performed on applicable persons of childbearing potential. All screening tests must be performed within 60 days of initiation of JNJ-64281802 study agent at Study Day -5 (Cohort 1) or Study Day -2 (Cohort 2). HIV screening must be performed within 2 weeks of JNJ-64281802 study agent administration. Pregnancy screening will occur at applicable screening visit(s), be repeated on the first day of JNJ-64281802 administration prior to administration, and on the day of inoculation with rDEN3delta30 prior to inoculation with rDEN3delta30. All clinically significant abnormalities will be reviewed with subjects and referral for follow-up care will be provided. Subjects will be determined to be eligible based on the inclusion and exclusion criteria for this protocol. For subjects who are eligible, the Study Day -5 (Cohort 1) or Study Day -2 (Cohort 2) visit will be scheduled for initiation of JNJ-64281802.
For Cohort 1: Subjects will present to the inpatient unit on Study Day -6. After eligibility criteria have been reviewed and confirmed, subjects will be admitted during this period of intensive PK sampling. Dosing with JNJ-64281802 or placebo will begin on Study Day -5. Discharge will occur on Study Day -4. Dosing with JNJ-64281802 will be observed in-clinic on Days -5, -4, -1, 1, 3, 5, 7, 9, 11, 14, 16, 18, and 21. Subjects will have phone contact on Days -3, -2, 2, 4, 6, 8, 10, 12, 13, 15, 17, 19, and 20 to record time of dose, time of last food intake, and review AEs and concomitant therapy. Daily dosing with JNJ-64281802 or placebo will occur from Study Day -5 through Study Day 21. On Study Day 21 subjects will present to the unit for a second intensive PK sampling period for a full day. On Study Day 1, all subjects will be challenged with rDEN3delta30.
For Cohort 2: Subjects will present to the inpatient unit on Study Day -3. After eligibility criteria have been reviewed and confirmed, subjects will be admitted during this period of intensive PK sampling. Dosing with JNJ-64281802 or placebo will begin on Study Day -2. Discharge will occur on Study Day 1. Dosing with JNJ-64281802 will be observed in-clinic on Days -2, -1, 1, 4, 6, 8, 11, 13, 15, 18, and 21 for the daily dosing regimen and on Days -2, -1, 1, 8 and 15 for the weekly dosing regimens. In the daily dosing regimen with JNJ-64281802 or placebo, twice daily dosing will occur from Study Day -2 to Study Day -1, and daily dosing from Study Day 1 to Study Day 21. In the weekly dosing regimens, twice daily dosing will occur from Study Day -2 to Study Day -1, and weekly dosing which will occur on Study Day 1, Study Day 8, and Study Day 15. On Study Day 21 for the daily regimen, and on Study Day 15 for the weekly regimens, subjects will present to the unit for a second intensive PK sampling period for a full day. On Study Day 1, all subjects will be challenged with rDEN3delta30.
During the inpatient visits on Study Day -6 to -4 (Cohort 1) and Study Day -3 to 1 (Cohort 2), the subjects will be evaluated by a clinician and will have blood drawn for clinical laboratory studies, virologic assays, and immunologic assays. During the outpatient visits subjects will return to the clinic for evaluation and for blood draw as specified in the Schedule of Procedures. Study Day 85 will be the final visit for Cohort 1. Study Day 85 will be the final visit for Cohort 2*. Subjects will have their temperature measured in clinic or measure their temperatures at home twice daily from Study Day 1 through Study Day 29.
Inclusion Criteria for receipt of Study Drug:
A volunteer must be:
Must be willing and able to adhere to the study requirements and lifestyle restrictions:
Exclusion Criteria for receipt of Study Drug:
Received or plans to receive:
Note: Vaccinations against DENV and Zika virus are not allowed until 90 days after last dose of study drug.
Known or suspected congenital or acquired immunodeficiency or use of (excluding topical and nasal) or immunosuppressive drugs within 28 days before first dose of study drug until 28 days following the last dose of study drug.
a. An immunosuppressive dose of corticosteroids is defined as greater than or equal to10 mg prednisone equivalent per day for grater than or equal to 14 days.
Exclusion Criteria for dengue virus injection:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sentinel high-dose. Four participants will be enrolled in Group 1a before enrolling the remaining participants to Group 1b (12 participants total in Group 1, all same dosing regimen). Note group 1a and group 1b are combined into one arm, because the dosing regimen is the same and they were not separated during final statistical analysis.
Drug: Cohort 1 - Group 1 JNJ High Dose
Group 2 includes Medium and low dose, 14 participants total. Enrolled after completion of Group 1a.
Drug: Cohort 1 - Group 2 JNJ Medium Dose
Group 2 includes Medium and low dose, 14 participants total. Enrolled after completion of Group 1a.
Drug: Cohort 1 - Group 2 JNJ Low Dose
Matching placebo. Note Group 1 placebo and group 2 placebo are combined per sponsor data analysis.
Drug: Cohort 1 - Group 1/2 Placebo
High dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days
Also known as: JNJ-64281802 (Sentinel high dose)
Medium dose: 200-mg loading dose for 5 days/50-mg maintenance dose for 21 days
Also known as: JNJ-64281802 (medium dose)
Low dose: 40-mg loading dose for 5 days/10-mg maintenance dose for 21 days
Also known as: JNJ-64281802 (low dose)
Matching placebo. Note Group 1 placebo and group 2 placebo are combined per sponsor data analysis.
Also known as: Placebo High Dose
Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection.
Area under the DENV-3 RNA viral load (VL) concentration-time curves from immediately before inoculation (baseline on Day 1) until Day 29. Notes: * Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/days1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml * Least square differences are calculated versus Placebo
Time frame: Day1-29
Number of Adverse Events to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).
Overall Summary of Treatment-emergent Adverse Events. Notes: * Overall phase=Pre-challenge+challenge+follow-up phases. * Solicited Systemic Reactogenicity AEs reported in the pre-challenge or follow-up phase are included.
Time frame: through study completion (Day 120)
Number of Subjects With Treatment-emergent AE's on JNJ64281802 That Are Appreciable/Observable on Physical Exam and Considered Related to Study Treatment.
* Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. * Adverse events are coded using MedDRA Version 25.0. * Related: Definitely related; Probably related; Possibly related. Not Related: Unlikely related; Unrelated. * Overall phase=Pre-challenge+challenge+follow-up phases. * Solicited Systemic Reactogenicity AEs reported in the pre-challenge or follow-up phase are included.
Time frame: through study completion (Day 120)
Recording of Vital Signs to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802)-Number of Subjects With Treatment-Emergent Abnormalities and Worst Graded Abnormalities Per Vital Sign Parameter.
Pulse (bpm), systolic and diastolic blood pressure (mmHg) measured on each clinic visit. -Subjects are counted only at the worst grade
Time frame: through study completion (Day 120)
12-lead ECG With Measurement of QTcF to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).
Number of participants with AE of prolonged QTcF.
Time frame: through study completion (Day 120)
12-lead ECG With Measurement of QRS Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).
Number of participants with AE of prolonged QRS interval.
Time frame: through study completion (Day 120)
12-lead ECG With Measurement of PR Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).
Number of participants with AE of prolonged PR interval.
Time frame: through study completion (Day 120)
Clinical Laboratory Assessments to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802).
Number of participants with treatment-emergent adverse events in laboratory assessments on JNJ 64281802
Time frame: through study completion (Day 120)
Assess the Dengue Infection-associated Adverse Events (Unwanted Medical Occurrence).
Number of Subjects with DENV-3 Infection-Associated AEs by Preferred Term and Severity - Solicited Systemic Reactogenicity Notes: - Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. The event experienced by the subject with the worst severity is used. If a subject has missing severity for a specific adverse event, the subject is only counted in the total column for that adverse event. - Adverse events are coded using MedDRA Version 25.0. - Only Solicited Systemic Reactogenicity AEs reported during Challenge Phase are included
Time frame: Day 1- Day 120
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Area Under the log10-transformed DENV 3 RNA VL Concentration-time Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29 (AUCD1 D29 [log10 VL])
Notes: - Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/day1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml - One subject in the High Dose Group has a missing sample on Day 29 and is therefore excluded from this analysis since the missing value could not be imputed according to the SAP rules - Least square differences are calculated versus Placebo
Time frame: Day 1- Day 29
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Peak of Detectable DENV-3 RNA (log10 VL).
Log10 Peak DENV-3 Viremia (log10 FFU/mL) * Tobit analysis of variance model with log10 Peak DENV-3 Viremia, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 0.18 log10 FFU/ml, with 3.0 FFU/ml the assumed limit of detection (LOD) and values \<LOD are imputed with 1.5 FFU/ml. (FFU=focus forming unit) * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.
Time frame: through study completion (Day 120)
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo for Duration in Days of Detectable DENV-3 RNA.
Duration of detectable DENV-3 RNA = Maximum day of (days with detectable DENV-3 RNA) - Minimum day of (days with detectable DENV-3 RNA) +1
Time frame: Day 1 - Day 120
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Time to First Onset by Days of Detectable DENV 3 RNA.
Time to first onset of detectable DENV-3 RNA is defined as the number of days between the date of inoculation and the date of the first onset of detectable DENV-3 RNA+1. If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Proportions are calculated with the number of subjects in each treatment arm as denominator.
Time frame: Day 1- Day 120
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Based on Presence of Detectable DENV-3 RNA as Measured by PCR (log10 VL) or Culture (log10 VL).
Number of participants with detectable DENV-3 viremia (defined as detectable DENV-3 Viremia result on at least 1 assessment in Study Days 1-29).
Time frame: Study Days 1- 29
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Area Under the Infectious Viremia Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29.
\- Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/day1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml
Time frame: Study Days 1-29
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Area Under the log10-transformed Viremia Curves.
Tobit Regression Results of Log10 AUC DENV-3 Viremia (log10 FFU/mL/day1-29). FFU = focus forming unit.
Time frame: Days 1-29
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Peak of Detectable Viremia Level
* Tobit analysis of variance model with log10 Peak DENV-3 Viremia, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 0.18 log10 FFU/ml, with 3.0 FFU/ml the assumed limit of detection (LOD) and values \<LOD are imputed with 1.5 FFU/ml. FFU = focus-forming unit. * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.
Time frame: through study completion (Day 120)
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Duration of Detectable Viremia.
* Duration of detectable DENV-3 Viremia = Maximum day of (days with detectable DENV-3 Viremia) * Minimum day of (days with detectable DENV-3 Viremia) +1 * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.
Time frame: through study completion (Day 120)
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Time to First Onset of Detectable Viremia.
Notes: * Time to first onset of detectable DENV-3 viremia is defined as the number of days between the date of inoculation and the date of the first onset of detectable DENV-3 viremia +1. * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result.
Time frame: Day 1-Day 120
Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Presence of Detectable Viremia.
\- Presence of detectable DENV-3 Viremia is defined as detectable DENV-3 Viremia result on at least 1 assessment in Study Days 1-29 - Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.
Time frame: Study Day 1-29
Assess How the Body Handles the Study Drug (JNJ-64281802) Following Repeated Oral Dosing- Maximum Observed Analyte Concentration (Cmax) During Inpatient Stay
Blood samples will be taken for measurement of plasma concentrations of JNJ-64281802 at specific time points in the study. Additional PK sampling may be performed on the non-intensive PK days (eg, in the event of an overdose) on other time points, in consultation with the JNJ drug development team. Plasma samples will be analyzed to determine concentrations of JNJ-64281802 using a validated, specific, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method under the supervision of the DDT's Bioanalytical Laboratory Department of Bioanalysis.
Time frame: Loading dose timeframe (inpatient stay): 5 days of loading dose for Cohort 1 and 2 days of loading dose for Cohort 2
Cmax: Maximum Observed Analyte Concentration of JNJ-64281802
Cmax: maximum observed analyte concentration during maintenance dose phase in ng/mL
Time frame: Day -5 to Day 21 (Cohort 1); Day -2 to Day 21 (Cohort 2 group 3); Day -2 to Day 15 (Cohort 2, Groups 4 and 5)
Cmin: Minimum Observed Analyte Concentration of JNJ-64281802
Cmin: Minimum observed analyte concentration in ng/mL
Time frame: Day -5 to Day 21 (Cohort 1); Day -2 to Day 21 (Cohort 2 group 3); Day -2 to Day 15 (Cohort 2, Groups 4 and 5)
Ctrough: Observed Analyte Concentration Just Before the Beginning or at the End of a Dosing Interval of JNJ-64281802
Ctrough: observed analyte concentration just prior to the beginning or at the end of a dosing interval in ng/mL
Time frame: Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
Cavg: Average Analyte Concentration Over the Dosing Interval (τ) Calculated as AUCτ/τ of JNJ-64281802
Time frame: Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
Tmax: the Actual Sampling Time (in Hours) to Reach the Maximum Observed Analyte Concentration of JNJ-64281802
Time frame: Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
Fluctuation Index (FI): Percentage Fluctuation (Variation) Between Maximum and Minimum Analyte Concentration at Steady-state, Calculated as 100 x ([Cmax - Cmin] / Cavg) of JNJ-64281802
Time frame: Day 21 (Cohort 1); Day 21 (Cohort 2 group 3); Day 15 (Cohort 2, Groups 4 and 5)
AUCτ: Area Under the Plasma Concentration-time Curve During the Dosing Interval (t Hours); Calculated by Linear-linear Trapezoidal Summation of JNJ-64281802
Time frame: Day 21 (Cohort 1); Day 21 (Cohort 2, Group 3); Day 15 (Cohort 2, Groups 4 & 5)
Occurrence of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.
Number of participants with anti-DENV-3 total IgM antibody titers (Occurrence of anti-DENV IgM is defined as a ratio against positive control of IgM antibodies (\>= 1.1) at any timepoint post-baseline)
Time frame: through study completion (Day 120)
Magnitude of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.
Peak Anti-DENV IgG Antibodies (U/mL)
Time frame: through study completion (Day 120)
Time to First Onset of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response.
If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Time to first onset of detectable anti-DENV IgM antibodies is defined as the number of days between the date of inoculation and the date of the first onset of positive anti-DENV IgM antibodies +1.
Time frame: through study completion (Day 120)
Time to First Onset of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response.
If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Time to first onset of detectable anti-DENV IgG antibodies is defined as the number of days between the date of inoculation and the date of the first onset of positive anti-DENV IgG antibodies +1.
Time frame: through study completion (Day 120)
The study follows an adaptive 2-stage design consisting of 2 cohorts enrolled in a staggered manner. Unblinded interim analysis of Cohort 1 was performed to determine the dosing regimens for Cohort 2 and provided results for the primary outcome.
| Milestone | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 1/2 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose | Cohort 2 - Group 3,4,5 Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 11 | 6 | 6 | 8 | 6 | 7 | 6 | 6 |
| Completed | 10 | 6 | 6 | 7 | 6 | 7 | 6 | 6 |
| Not completed | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Area under the DENV-3 RNA viral load (VL) concentration-time curves from immediately before inoculation (baseline on Day 1) until Day 29. Notes: * Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/days1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml * Least square differences are calculated versus Placebo
| Log10 AUC VL (log10 copies/mL/28days) | Cohort 1 - Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 Group 2 - JNJ Low Dose | Cohort 1 Group 2 - JNJ Medium Dose | Cohort 1 Group 1 - JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 Group 3 - JNJ Daily Dose | Cohort 2 Group 4 - JNJ Weekly High Dose | Cohort 2 Group 5 - JNJ Weekly Low Dose |
|---|---|---|---|---|---|---|---|---|
| Assess the Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo in Terms of Reduction of Dengue Infection. | 5.01 (4.40 to 5.62) | 5.20 (4.55 to 5.86) | 4.71 (4.05 to 5.38) | 2.98 (2.38 to 3.59) | 5.20 (4.34 to 6.05) | 2.50 (1.43 to 3.56) | 1.87 (0.59 to 3.15) | 1.67 (0.34 to 2.99) |
Overall Summary of Treatment-emergent Adverse Events. Notes: * Overall phase=Pre-challenge+challenge+follow-up phases. * Solicited Systemic Reactogenicity AEs reported in the pre-challenge or follow-up phase are included.
| Participants | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Participants with 1 or more AE (Any AE) | 8 | 6 | 6 | 11 | 6 | 6 | 7 | 6 |
| Participants with 1 or more AE related to study treatment | 3 | 3 | 4 | 5 | 2 | 1 | 0 | 3 |
| Participants with 1 or more AE related to inoculation with DENV-3 | 5 | 5 | 5 | 3 | 4 | 0 | 3 | 2 |
| Participants with 1 or more AE leading to discontinuation of any study treatment | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with 1 or more AE leading to termination of study participation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with 1 or more AE of Mild severity | 3 | 2 | 2 | 5 | 3 | 5 | 5 | 4 |
| Participants with 1 or more AE of Moderate severity | 4 | 4 | 3 | 5 | 0 | 1 | 0 | 2 |
| Participants with 1 or more AE of Severe severity | 1 | 0 | 1 | 1 | 3 | 0 | 2 | 0 |
| Participants with 1 or more AE of Life-Threatening severity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with 1 or more serious AE | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Participants with 1 or more serious AE related to study treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with 1 or more serious AE related to inoculation with DENV-3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with 1 or more AEs leading to death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with 1 or more related AEs leading to death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
* Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. * Adverse events are coded using MedDRA Version 25.0. * Related: Definitely related; Probably related; Possibly related. Not Related: Unlikely related; Unrelated. * Overall phase=Pre-challenge+challenge+follow-up phases. * Solicited Systemic Reactogenicity AEs reported in the pre-challenge or follow-up phase are included.
| Participants | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Treatment-emergent AE's on JNJ64281802 That Are Appreciable/Observable on Physical Exam and Considered Related to Study Treatment. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Pulse (bpm), systolic and diastolic blood pressure (mmHg) measured on each clinic visit. -Subjects are counted only at the worst grade
| participants | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Tachycardia (Grade 1) | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 |
| Diastolic Blood Pressure Hypertension (Grade 1) | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 1 |
| Systolic Blood Pressure Hypertension (Grade 3) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Systolic Blood Pressure Hypertension (Grade 1) | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Bradycardia (Grade 1) | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Bradycardia (Grade 2) | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 |
| Bradycardia (Grade 3) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Diastolic Blood Pressure Hypertension (Grade 2) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Diastolic Blood Pressure Hypertension (Grade 3) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Systolic Blood Pressure Hypotension (Grade 1) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Systolic Blood Pressure Hypotension (Grade 2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Number of participants with AE of prolonged QTcF.
| Participants | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo |
|---|---|---|---|---|---|---|---|---|
| 12-lead ECG With Measurement of QTcF to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802). | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with AE of prolonged QRS interval.
| Participants | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo |
|---|---|---|---|---|---|---|---|---|
| 12-lead ECG With Measurement of QRS Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802). | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with AE of prolonged PR interval.
| Participants | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo |
|---|---|---|---|---|---|---|---|---|
| 12-lead ECG With Measurement of PR Interval to Assess the Safety and Tolerability of the Study Drug (JNJ 64281802). | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with treatment-emergent adverse events in laboratory assessments on JNJ 64281802
| Participants | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Hemoglobin Decreased | 0 | 1 | 0 | 3 | 3 | 0 | 1 | 2 |
| AST increased | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Hyperglycemia | 1 | 0 | 1 | 1 | 1 | 0 | 3 | 1 |
Number of Subjects with DENV-3 Infection-Associated AEs by Preferred Term and Severity - Solicited Systemic Reactogenicity Notes: - Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. The event experienced by the subject with the worst severity is used. If a subject has missing severity for a specific adverse event, the subject is only counted in the total column for that adverse event. - Adverse events are coded using MedDRA Version 25.0. - Only Solicited Systemic Reactogenicity AEs reported during Challenge Phase are included
| Participants | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Fever — N/a | 7 | 6 | 5 | 11 | 5 | 6 | 6 | 6 |
| Fever — Mild | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Fever — Moderate | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Headache — N/a | 2 | 0 | 3 | 7 | 1 | 2 | 5 | 3 |
| Headache — Mild | 4 | 4 | 2 | 3 | 5 | 3 | 2 | 3 |
| Headache — Moderate | 2 | 2 | 1 | 1 | 0 | 1 | 0 | 0 |
| Maculopapular rash — N/a | 1 | 1 | 2 | 8 | 2 | 5 | 6 | 5 |
| Maculopapular rash — Mild | 6 | 3 | 3 | 3 | 3 | 1 | 1 | 1 |
| Maculopapular rash — Moderate | 1 | 2 | 1 | 0 | 1 | 0 | 0 | 0 |
| Myalgia — N/a | 5 | 1 | 3 | 11 | 2 | 5 | 5 | 6 |
| Myalgia — Mild | 3 | 4 | 2 | 0 | 2 | 1 | 2 | 0 |
| Myalgia — Moderate | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 |
| Arthralgia — N/a | 6 | 4 | 5 | 10 | 2 | 5 | 5 | 6 |
| Arthralgia — Mild | 2 | 1 | 0 | 0 | 2 | 1 | 2 | 0 |
| Arthralgia — Moderate | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 0 |
| Retro-orbital pain — N/a | 5 | 3 | 4 | 11 | 3 | 3 | 7 | 6 |
| Retro-orbital pain — Mild | 2 | 3 | 2 | 0 | 3 | 3 | 0 | 0 |
| Retro-orbital pain — Moderate | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fatigue — N/a | 3 | 2 | 5 | 8 | 1 | 4 | 4 | 3 |
| Fatigue — Mild | 4 | 2 | 1 | 3 | 5 | 1 | 3 | 3 |
| Fatigue — Moderate | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Nausea — N/a | 6 | 3 | 5 | 10 | 5 | 5 | 5 | 4 |
| Nausea — Mild | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 2 |
| Nausea — Moderate | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Abdominal pain — N/a | 7 | 3 | 5 | 11 | 5 | 5 | 7 | 5 |
| Abdominal pain — Mild | 1 | 2 | 1 | 0 | 1 | 1 | 0 | 1 |
| Abdominal pain — Moderate | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vomiting — N/a | 6 | 5 | 6 | 11 | 5 | 6 | 6 | 6 |
| Vomiting — Mild | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Vomiting — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Diarrhea — N/a | 7 | 4 | 6 | 11 | 5 | 4 | 3 | 4 |
| Diarrhea — Mild | 1 | 2 | 0 | 0 | 1 | 2 | 3 | 2 |
| Diarrhea — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Decreased appetite — N/a | 5 | 5 | 4 | 11 | 4 | 5 | 6 | 4 |
| Decreased appetite — Mild | 3 | 1 | 2 | 0 | 2 | 1 | 1 | 2 |
| Decreased appetite — Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Notes: - Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/day1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml - One subject in the High Dose Group has a missing sample on Day 29 and is therefore excluded from this analysis since the missing value could not be imputed according to the SAP rules - Least square differences are calculated versus Placebo
| log10 copies/ml/28days | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Area Under the log10-transformed DENV 3 RNA VL Concentration-time Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29 (AUCD1 D29 [log10 VL]) | 2.98 (2.38 to 3.59) | 4.71 (4.05 to 5.38) | 5.2 (4.55 to 5.86) | 5.01 (4.4 to 5.62) | 5.2 (4.34 to 6.05) | 2.5 (1.43 to 3.56) | 1.87 (0.59 to 3.15) | 1.67 (0.34 to 2.99) |
Log10 Peak DENV-3 Viremia (log10 FFU/mL) * Tobit analysis of variance model with log10 Peak DENV-3 Viremia, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 0.18 log10 FFU/ml, with 3.0 FFU/ml the assumed limit of detection (LOD) and values \<LOD are imputed with 1.5 FFU/ml. (FFU=focus forming unit) * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.
| Log10 Peak DENV-3 Viremia (log10 FFU/mL) | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo by Reviewing the Peak of Detectable DENV-3 RNA (log10 VL). | 1.70 (1.01 to 2.4) | 2.11 (1.36 to 2.87) | 1.46 (0.68 to 2.24) | 0.18 (-0.56 to 9.92) | 2.13 (1.34 to 2.91) | -0.98 (-2.27 to 0.31) | -0.37 (-1.52 to 0.79) | NA (NA to NA) |
Duration of detectable DENV-3 RNA = Maximum day of (days with detectable DENV-3 RNA) - Minimum day of (days with detectable DENV-3 RNA) +1
| Days | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo for Duration in Days of Detectable DENV-3 RNA. | 1.40 ± 2.366 | 1.33 ± 1.366 | 4.67 ± 2.658 | 3.86 ± 1.069 | 7.5 ± 1.761 | 2.67 ± 4.131 | 1.33 ± 3.266 | 1 ± 2.449 |
Time to first onset of detectable DENV-3 RNA is defined as the number of days between the date of inoculation and the date of the first onset of detectable DENV-3 RNA+1. If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Proportions are calculated with the number of subjects in each treatment arm as denominator.
| Days to first onset of detectable DENV-3 | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Time to First Onset by Days of Detectable DENV 3 RNA. | 3 (2 to NA) | 5 (5 to NA) | 11 (5 to NA) | NA (7 to NA) | 4 (4 to NA) | NA (8 to NA) | NA (8 to NA) | NA (15 to NA) |
Number of participants with detectable DENV-3 viremia (defined as detectable DENV-3 Viremia result on at least 1 assessment in Study Days 1-29).
| Participants | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo Based on Presence of Detectable DENV-3 RNA as Measured by PCR (log10 VL) or Culture (log10 VL). | 3 | 4 | 6 | 7 | 6 | 1 | 1 | 0 |
\- Tobit analysis of variance model with log10 AUC DENV-3 RNA D1-29, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 2.70 log10 copies/ml/day1-29, with 36 copies/ml the assumed limit of detection (LO) and values \<LOD are imputed with 18 copies/ml
| log10 copies/ml/28days | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Area Under the Infectious Viremia Curves From Immediately Before Inoculation (Baseline on Day 1) Until Day 29. | 2.98 (2.38 to 3.59) | 4.71 (4.05 to 5.38) | 5.20 (4.55 to 5.86) | 5.01 (4.40 to 5.62) | 5.20 (4.34 to 6.05) | 2.50 (1.43 to 3.56) | 1.87 (0.59 to 3.15) | 1.67 (0.34 to 2.99) |
Tobit Regression Results of Log10 AUC DENV-3 Viremia (log10 FFU/mL/day1-29). FFU = focus forming unit.
| log10 FFU/mL/day | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Area Under the log10-transformed Viremia Curves. | 1.57 (1.11 to 2.03) | 2.38 (1.90 to 2.87) | 2.63 (2.16 to 3.09) | 2.37 (1.94 to 2.80) | 2.68 (2.22 to 3.14) | 0.86 (0.09 to 1.64) | 1.28 (0.60 to 1.96) | NA (NA to NA) |
* Tobit analysis of variance model with log10 Peak DENV-3 Viremia, rounded to 2 decimal places, as dependent variable and study drug as fixed covariate. A normally distributed error term is used. Values are left censored at the value 0.18 log10 FFU/ml, with 3.0 FFU/ml the assumed limit of detection (LOD) and values \<LOD are imputed with 1.5 FFU/ml. FFU = focus-forming unit. * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.
| log10 FFU/ml | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Peak of Detectable Viremia Level | 0.18 (-0.56 to 0.92) | 1.46 (0.68 to 2.24) | 2.11 (1.36 to 2.87) | 1.70 (1.01 to 2.40) | 2.13 (1.34 to 2.91) | -0.98 (-2.27 to 0.31) | -0.37 (-1.52 to 0.79) | NA (NA to NA) |
* Duration of detectable DENV-3 Viremia = Maximum day of (days with detectable DENV-3 Viremia) * Minimum day of (days with detectable DENV-3 Viremia) +1 * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.
| Days | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on the Duration of Detectable Viremia. | 1.40 ± 2.366 | 1.33 ± 1.366 | 4.67 ± 2.658 | 3.86 ± 1.069 | 7.50 ± 1.761 | 2.67 ± 4.131 | 1.33 ± 3.266 | 1.00 ± 2.449 |
Notes: * Time to first onset of detectable DENV-3 viremia is defined as the number of days between the date of inoculation and the date of the first onset of detectable DENV-3 viremia +1. * Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result.
| Days to onset of DENV-3 RNA Viremia | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Time to First Onset of Detectable Viremia. | 5.00 (5.00 to NA) | 7.50 (7.00 to NA) | 16.00 (9.00 to NA) | NA (9.00 to NA) | 6.00 (4.00 to NA) | NA (11.00 to NA) | NA (11.00 to NA) | — |
\- Presence of detectable DENV-3 Viremia is defined as detectable DENV-3 Viremia result on at least 1 assessment in Study Days 1-29 - Assessments of DENV-3 infectious virus (Viremia) are only performed for samples that have detectable DENV-3 RNA result. For samples where the DENV-3 RNA result is below the limit of detection, the corresponding Viremia result is imputed with 1.5 FFU/ml. For samples where the DENV-3 RNA is not available or the DENV-3 RNA result is above LOD, corresponding DENV Infectious virus (Viremia) results are not imputed.
| Participants | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Antiviral Activity of the Study Drug (JNJ 64281802) Versus Placebo on Presence of Detectable Viremia. | 3 | 4 | 6 | 7 | 6 | 1 | 1 | 0 |
Blood samples will be taken for measurement of plasma concentrations of JNJ-64281802 at specific time points in the study. Additional PK sampling may be performed on the non-intensive PK days (eg, in the event of an overdose) on other time points, in consultation with the JNJ drug development team. Plasma samples will be analyzed to determine concentrations of JNJ-64281802 using a validated, specific, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method under the supervision of the DDT's Bioanalytical Laboratory Department of Bioanalysis.
| Cmax (ng/mL) | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|
| Assess How the Body Handles the Study Drug (JNJ-64281802) Following Repeated Oral Dosing- Maximum Observed Analyte Concentration (Cmax) During Inpatient Stay | 1259 ± 337 | 553 ± 232 | 104 ± 55.1 | 2141 ± 1051 | 1894 ± 866 | 1187 ± 335 |
Cmax: maximum observed analyte concentration during maintenance dose phase in ng/mL
| Cmax (ng/mL) | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|
| Cmax: Maximum Observed Analyte Concentration of JNJ-64281802 | 3242 ± 474 | 882 ± 198 | 162 ± 9.29 | 5245 ± 1745 | 5410 ± 1854 | 2826 ± 843 |
Cmin: Minimum observed analyte concentration in ng/mL
| ng/mL | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|
| Cmin: Minimum Observed Analyte Concentration of JNJ-64281802 | 2438 ± 391 | 608 ± 169 | 106 ± 23.5 | 3845 ± 1520 | 1455 ± 310 | 989 ± 463 |
Ctrough: observed analyte concentration just prior to the beginning or at the end of a dosing interval in ng/mL
| ng/mL | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|
| Ctrough: Observed Analyte Concentration Just Before the Beginning or at the End of a Dosing Interval of JNJ-64281802 | 2549 ± 344 | 628 ± 190 | 112 ± 26.9 | 4027 ± 1166 | 1500 ± 356 | 1228 ± 449 |
| ng/mL | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|
| Cavg: Average Analyte Concentration Over the Dosing Interval (τ) Calculated as AUCτ/τ of JNJ-64281802 | 2947 ± 504 | 743 ± 168 | 133 ± 15.4 | 4717 ± 1467 | 2502 ± 678 | 1571 ± 528 |
| hours | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|
| Tmax: the Actual Sampling Time (in Hours) to Reach the Maximum Observed Analyte Concentration of JNJ-64281802 | 8.03 (8.00 to 12.10) | 8.03 (8.00 to 8.63) | 8.05 (6.02 to 8.45) | 8.01 (4.00 to 12.07) | 4.01 (4.00 to 4.02) | 8.07 (4.00 to 12.03) |
| % fluctuation | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|
| Fluctuation Index (FI): Percentage Fluctuation (Variation) Between Maximum and Minimum Analyte Concentration at Steady-state, Calculated as 100 x ([Cmax - Cmin] / Cavg) of JNJ-64281802 | 27.5 ± 4.63 | 38.4 ± 17.1 | 43.6 ± 16.3 | 32.7 ± 20.0 | 155 ± 38.1 | 122 ± 25.1 |
| ng.h/mL | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|
| AUCτ: Area Under the Plasma Concentration-time Curve During the Dosing Interval (t Hours); Calculated by Linear-linear Trapezoidal Summation of JNJ-64281802 | 70717 ± 12093 | 17821 ± 4028 | 3186 ± 369 | 113216 ± 35203 | 420271 ± 113827 | 263861 ± 88651 |
Number of participants with anti-DENV-3 total IgM antibody titers (Occurrence of anti-DENV IgM is defined as a ratio against positive control of IgM antibodies (\>= 1.1) at any timepoint post-baseline)
| Participants | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Occurrence of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response. | 4 | 4 | 6 | 7 | 6 | 2 | 1 | 1 |
Peak Anti-DENV IgG Antibodies (U/mL)
| Peak Anti-DENV Ig Antibodies (U/mL) | Cohort 1 - Group 1 JNJ High Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Magnitude of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response. | 14.25 ± 16.177 | 27.97 ± 33.311 | 67.27 ± 65.534 | 71.97 ± 43.603 | 151.57 ± 55.683 | 47.21 ± 66.334 | 16.32 ± 35.829 | 4.79 ± 6.804 |
If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Time to first onset of detectable anti-DENV IgM antibodies is defined as the number of days between the date of inoculation and the date of the first onset of positive anti-DENV IgM antibodies +1.
| Days | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Time to First Onset of Anti-DENV-3 Total IgM Antibody Titers to Assess the Anti-Dengue Immune Response. | 14.00 (13.00 to NA) | 16.00 (11.00 to NA) | 26.00 (16.00 to NA) | NA (1.00 to NA) | 14.00 (13.00 to NA) | NA (21.00 to NA) | NA (18.00 to NA) | NA (33.00 to NA) |
If no detectable event is measured, the participant will be censored at the last available sample with a valid event result. Notes: \- Time to first onset of detectable anti-DENV IgG antibodies is defined as the number of days between the date of inoculation and the date of the first onset of positive anti-DENV IgG antibodies +1.
| Days | Cohort 1 Group 1 Placebo and Cohort 1 Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4, and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose |
|---|---|---|---|---|---|---|---|---|
| Time to First Onset of Anti-DENV-3 Total IgG Antibody Titers to Assess the Anti-Dengue Immune Response. | 21.00 (13.00 to 21.00) | 26.00 (16.00 to NA) | NA (23.00 to NA) | NA (23.00 to NA) | 16.50 (11.00 to NA) | NA (29.00 to NA) | NA (85.00 to NA) | — |
Collected over Adverse event data was collected for the duration of the enrollment period (90 days total for Cohort 1; 122 days total for Cohort 2) in relation to baseline. Subjects began the study drug (or placebo) on Day -5 (Cohort 1) or Day -2 (Cohort 2) followed by challenge with DENV-3 on Day 1. Subjects were followed for AE's through completion of enrollment at Day 85 (Cohort 1) or Day 120 (Cohort 2).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Cohort 1 | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| JNJ-64281802 Low Dose | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| JNJ-64281802 Medium Dose | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| JNJ-64281802 High Dose | 0/11 (0%) | 0/11 (0%) | 11/11 (100%) |
| Placebo Cohort 2 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| JNJ-64281802 Daily Dose (Cohort 2 Group 3) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| JNJ-64281802 Weekly Dose (Cohort 2 Group 4) | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| JNJ-64281802 Weekly Dose (Cohort 2 Group 5) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Placebo Cohort 1 | JNJ-64281802 Low Dose | JNJ-64281802 Medium Dose | JNJ-64281802 High Dose | Placebo Cohort 2 | JNJ-64281802 Daily Dose (Cohort 2 Group 3) | JNJ-64281802 Weekly Dose (Cohort 2 Group 4) | JNJ-64281802 Weekly Dose (Cohort 2 Group 5) |
|---|---|---|---|---|---|---|---|---|
| Drug overdosePsychiatric disorders | 0/8 | 0/6 | 0/6 | 0/11 | 0/6 | 0/6 | 1/7 | 0/6 |
| Creatinine Kinase HighMusculoskeletal and connective tissue disorders | 1/8 | 0/6 | 0/6 | 0/11 | 0/6 | 0/6 | 0/7 | 0/6 |
| AST increasedGastrointestinal disorders | 1/8 | 0/6 | 0/6 | 0/11 | 0/6 | 0/6 | 0/7 | 0/6 |
| Event | Placebo Cohort 1 | JNJ-64281802 Low Dose | JNJ-64281802 Medium Dose | JNJ-64281802 High Dose | Placebo Cohort 2 | JNJ-64281802 Daily Dose (Cohort 2 Group 3) | JNJ-64281802 Weekly Dose (Cohort 2 Group 4) | JNJ-64281802 Weekly Dose (Cohort 2 Group 5) |
|---|---|---|---|---|---|---|---|---|
| Rash Maculo-papular (DENV Infection Associated)Skin and subcutaneous tissue disorders | 7/8 | 5/6 | 4/6 | 3/11 | 4/6 | 1/6 | 1/7 | 1/6 |
| Headache (DENV Infection Associated)General disorders | 5/8 | 4/6 | 2/6 | 3/11 | 5/6 | 4/6 | 2/7 | 3/6 |
| Fatigue (DENV Infection Associated)General disorders | 5/8 | 4/6 | 1/6 | 3/11 | 5/6 | 2/6 | 3/7 | 3/6 |
| Myalgia (DENV Infection Associated)General disorders | 3/8 | 5/6 | 3/6 | 0/11 | 4/6 | 1/6 | 2/7 | 0/6 |
| Vessel Puncture Site BruiseGeneral disorders | 0/8 | 4/6 | 3/6 | 4/11 | 1/6 | 1/6 | 3/7 | 3/6 |
| Diarrhea (DENV Infection Associated)Gastrointestinal disorders | 1/8 | 2/6 | 0/6 | 0/11 | 1/6 | 2/6 | 4/7 | 2/6 |
| Hemoglobin DecreasedInvestigations | 0/8 | 1/6 | 0/6 | 3/11 | 3/6 | 0/6 | 1/7 | 1/6 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/8 | 1/6 | 0/6 | 0/11 | 0/6 | 1/6 | 1/7 | 3/6 |
| LymphadenopathyBlood and lymphatic system disorders | 1/8 | 2/6 | 3/6 | 0/11 | 2/6 | 0/6 | 0/7 | 0/6 |
| Eye Pain (DENV Infection Associated)Eye disorders | 3/8 | 3/6 | 2/6 | 0/11 | 3/6 | 3/6 | 0/7 | 0/6 |
Group 1 Placebo and Group 2 Placebo are combined in one category to be consistent with how data was analyzed. Group 2 placebo were not analyzed on their own (group 1/2 placebos were combined during analysis).
| Age, Categorical(Participants) | Cohort 1 - Group 1 and Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4 and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 6 | 6 | 11 | 6 | 6 | 7 | 6 | 56 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1 - Group 1 and Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4 and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 4 | 5 | 7 | 4 | 1 | 4 | 4 | 33 |
| Male | 4 | 2 | 1 | 4 | 2 | 5 | 3 | 2 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 - Group 1 and Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4 and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 7 | 5 | 6 | 11 | 5 | 6 | 7 | 6 | 53 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Cohort 1 - Group 1 and Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4 and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 3 | 5 | 2 | 1 | 2 | 0 | 19 |
| White | 3 | 2 | 2 | 3 | 3 | 5 | 5 | 5 | 28 |
| More than one race | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 3 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Cohort 1 - Group 1 and Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4 and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 8 | 6 | 6 | 11 | 6 | 6 | 7 | 6 | 56 |
| PRNT (50) DENV(participants) | Cohort 1 - Group 1 and Group 2 Placebo | Cohort 1 - Group 2 JNJ Low Dose | Cohort 1 - Group 2 JNJ Medium Dose | Cohort 1 - Group 1 JNJ High Dose | Cohort 2 - Group 3, Group 4 and Group 5 Placebo | Cohort 2 - Group 3 JNJ Daily Dose | Cohort 2 - Group 4 JNJ Weekly Dose | Cohort 2 - Group 5 JNJ Weekly Dose | Total |
|---|---|---|---|---|---|---|---|---|---|
| PRNT (50) DENV-1 <=10 | 8 | 6 | 6 | 11 | 6 | 6 | 7 | 6 | 56 |
| PRNT (50) DENV-2 <=10 | 8 | 6 | 6 | 11 | 6 | 6 | 7 | 6 | 56 |
| PRNT (50) DENV-3 <=10 | 8 | 6 | 6 | 11 | 6 | 6 | 7 | 6 | 56 |
| PRNT (50) DENV-4 <=10 | 8 | 6 | 6 | 11 | 6 | 6 | 7 | 6 | 56 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2022 to primary completion in May 2023, 15 months.
Results were first posted in Apr 2025, 1 year 11 months after primary completion.
Of 31 phase 2 interventional studies under Dengue, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 38. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Allergy and Infectious Diseases (NIAID) →